Thank you for your words! And feel free to reach out for more info

Thank you to all co-authors: Matteo dugo, Marco Barreca, Giampaolo Bianchini, Luca Gianni et al, funding, #AIRC, #BCRF, fondazionemichelangelo.org @fgbonadonna.bsky.social and all patients!

Recent findings from the #PATINA trial further confirmed the efficacy of combined targeted treatment in HER2+ER+ BC. We provide a better understanding of #drivers and #dynamics of HER2+ER+ tumour response, towards to the design of de-escalation or #escalation strategies.

The HighHigh group showed #dysfunctional immune infiltration and overexpression of #therapeutic #targets like #PAK4 at baseline. The LowLow group exhibited a #LuminalA phenotype by the end of treatment

Stratification based on Ki67 at Day14 and at surgery defined three response groups (Ki67 HighHigh, LowHigh, LowLow), with divergent tumour and stroma expression dynamics

We performed #RNAseq and #TIL assessment in serial biopsies from the NA-PHER2 trial. High #immune #infiltration and low #ER signalling at baseline correlated with #pCR, while #TP53 mutations associated with high Day14 #Ki67

HER2+ER+ BC shows lower response to chemo+antiHER2 treatment. #Biomarker-guided alternative approaches could improve #outcomes and reduce #toxicities.
#NAPHER2 trial investigated #neoadjuvant #HER2 blockade and CDK4/6 inhibition with or without #endocrine therapy in HER2+ER+ BC.